Evidence map›Paper›PMID 40227439›Full record

ReviewRadiologie (Heidelberg, Germany)2025

[Importance of peptide receptor radionuclide therapy for the management of neuroendocrine tumours].

I Ciuciulkaite, K Herrmann, H Lahner

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Imaging diagnostics for diseases of the small bowel].Radiologie (Heidelberg, Germany) · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

I CiuciulkaiteKlinik für Nuklearmedizin, Universitätsmedizin Essen, Universität Duisburg-Essen, Essen, Deutschland. ieva.ciuciulkaite@uk-essen.de.
K HerrmannKlinik für Nuklearmedizin, Universitätsmedizin Essen, Universität Duisburg-Essen, Essen, Deutschland.
H LahnerKlinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsmedizin Essen, Universität Duisburg-Essen, Essen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine tumours (NETs) are rare, heterogeneous neoplasms that often express somatostatin receptors (SSTRs). This allows targeted peptide receptor radionuclide therapy (PRRT) for NETs. PRRT is currently indicated as second- or third-line therapy for metastatic or unresectable, progressive, SSTR-positive NETs of grade (G) 1 or 2. Adequate bone marrow reserves as well as renal and hepatic function are required for PRRT. The most commonly used radiopharmaceutical for PRRT is

Indexed as

Neuroendocrine TumorsOctreotideRadioisotopesRadiopharmaceuticalsReceptors, PeptideReceptors, SomatostatinHumansLutetiumOrganometallic CompoundsLutetiumOctreotideOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsReceptors, PeptideReceptors, SomatostatinNETPeptide receptorsPRRTRadionuclidesSomatostatin receptors

Identifiers

PMID40227439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.